SAB Biotherapeutics annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
SAB Biotherapeutics Debt-to-Equity Ratio Growth & History (SABS)
SAB Biotherapeutics's debt-to-equity ratio was 0.04 for fiscal 2025.
View full SAB Biotherapeutics company overviewSAB Biotherapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.04 | −0.13 | −76.78% |
| 2024 | 2024-12-31 | 0.17 | 0.08 | +99.60% |
| 2023 | 2023-12-31 | 0.08 | −0.08 | −48.95% |
| 2022 | 2022-12-31 | 0.17 | −0.01 | −4.75% |
| 2021 | 2021-12-31 | 0.17 | −463.17 | −99.96% |
| 2020 | 2020-12-31 | 463.34 | — | — |
SAB Biotherapeutics quarterly debt-to-equity ratio
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.02 | −0.51 | −95.53% |
| Q1 2026 | 2026-03-31 | 0.03 | −0.28 | −91.25% |
| Q4 2025 | 2025-12-31 | 0.04 | −0.13 | −76.78% |
| Q3 2025 | 2025-09-30 | 0.04 | −0.09 | −69.40% |
| Q2 2025 | 2025-06-30 | 0.53 | 0.43 | +421.19% |
| Q1 2025 | 2025-03-31 | 0.31 | 0.22 | +255.18% |
| Q4 2024 | 2024-12-31 | 0.17 | 0.08 | +99.60% |
| Q3 2024 | 2024-09-30 | 0.12 | −0.15 | −54.54% |
| Q2 2024 | 2024-06-30 | 0.10 | −0.14 | −57.83% |
| Q1 2024 | 2024-03-31 | 0.09 | −0.12 | −57.49% |
| Q4 2023 | 2023-12-31 | 0.08 | −0.08 | −48.95% |
| Q3 2023 | 2023-09-30 | 0.27 | 0.08 | +42.78% |
| Q2 2023 | 2023-06-30 | 0.24 | 0.08 | +48.74% |
| Q1 2023 | 2023-03-31 | 0.21 | 0.05 | +32.76% |
| Q4 2022 | 2022-12-31 | 0.17 | −0.01 | −4.75% |
| Q3 2022 | 2022-09-30 | 0.19 | — | — |
| Q2 2022 | 2022-06-30 | 0.16 | — | — |
| Q1 2022 | 2022-03-31 | 0.15 | — | — |
| Q4 2021 | 2021-12-31 | 0.17 | — | — |
SAB Biotherapeutics debt-to-equity ratio trends
Over the last five fiscal years, SAB Biotherapeutics's debt-to-equity ratio decreased from 463.34 to 0.04, a change of −463.30. The latest reported quarter, Q2 2026, shows 0.02.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SAB Biotherapeutics source filings ↗